Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM336 in POEMS Syndrome
NCT07115654Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of gamgertamig in POEMS syndrome (POEMS), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Aug 2025; status: recruiting.
02
Drugs
gamgertamig
03
Conditions
POEMS syndrome (POEMS)
Beyond the preview
Go deeper on NCT07115654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07115654.